Table 3.
The list of clinical trials of HCQ against COVID-19 in China.
| Number | Registration number | Registration name | Type of clinical trial | Registration date of clinical trial | Group | Progress | Anticipated execute time | |
|---|---|---|---|---|---|---|---|---|
| Intervention | Comparator | |||||||
| 1 | ChiCTR2000029559 | Hydroxychloroquine sulfate in patients with COVID-19 | Intervention study | 4/2/2020 | Hydroxychloroquine 200 mg bid via oral | Placebo group: Starch pill bid via oral | Complete | From2020-01-31 To 2020-02-29 The time of sharing IPD Within 6 months after the trial complete |
| 2 | ChiCTR2000029740 | Study on the effectiveness of hydroxychloroquine sulfate in treating COVID-19 | Intervention study | 11/2/2020 | Hydroxychloroquine 200 mg bid via oral | Conventional therapy | Recruiting | From 2020-02-11 To 2020-02-29 The time of sharing IPD Within 6 months after the trial complete |
| 3 | ChiCTR2000029760 | Study on the effectiveness of hydroxychloroquine sulfate in treating mild/normal COVID-19 | Intervention study | 12/2/2020 | Hydroxychloroquin | Lopinavir/Ritonavir | Canceled due to lack of patients. | From 2020-02-12 To 2020-08-11 |
| 4 | ChiCTR2000029761 | Study on the effectiveness and safety of hydroxychloroquine sulfate in treating mild/normal COVID-19 | Intervention study | 12/2/2020 | Low-dose group:Low-dose hydroxychloroquine and conventional therapy Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy High-dose group:High-dose hydroxychloroquine and conventional therapy |
Conventional therapy | Canceled due to lack of patients. | From 2020-02-13 To 2020-04-30 |
| 5 | ChiCTR2000029762 | Study on the effectiveness and safety of hydroxychloroquine sulfate in treating severe/critical COVID-19 | Intervention study | 12/2/2020 | Conventional treated with hydroxychloroquine | Conventional treatment | Canceled due to lack of patients. | From 2020-02-12 |
| 6 | ChiCTR2000029868 | Multicenter clinical study on the treatment of COVID-19 with hydroxychloroquine sulfate | Intervention study | 15/2/2020 | Hydroxychloroquine sulfate 1200 mg daily for 3 days followed by a maintenance dose of 800 mg daily (total treatment duration: two or 3 weeks for patients with mild to moderate or severe disease, respectively). | Conventional treatment | Complete | From 2020-02-06 To 2020-06-30 The time of sharing IPD Within 6 months after the trial complete |
| 7 | ChiCTR2000029992 | A prospective, open randomized controlled trial of chloroquine phosphate and hydroxychloroquine sulfate in patients with COVID-19 | Intervention study | 18/2/2020 | Chloroquine phosphate gloup: Chloroquine phosphate 1.0 g with 2 days for the first dose, 0.5 g for 12 days from the 3rd day Hydroxychloroquine sulfate gloup: Hydroxychloroquine sulfate 0.2 g BID for 14 days |
Recommended treatment plan for severe and critical cases in COVID-19 | Not yet recruiting. | From2020-02-17 To 2020-05-20 The time of sharing IPD Within 6 months after the trial complete |
| 8 | ChiCTR2000030054 | An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel COVID-19 | Intervention study | 22/2/2020 | Hydroxychloroquine sulfate gloup: Hydroxychloroquine sulfate 0.2 g BID for 14 days Chloroquine phosphate gloup: The first dose of chloroquine phosphate was 1 g for 2 days, and the 3rd day was 0.5 g for 12 days |
Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan | Not yet recruiting. | From 2020-02-22 To 2020-05-21 The time of sharing IPD Within 6 months after the trial complete |
| 9 | ChiCTR2000031174 | Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel COVID-19 | Intervention study | 23/3/2020 | Hydroxychloroquine | Placebo | Not yet recruiting. | From 2020-03-23 To 2020-09-30 The time of sharing IPD Within 6 months after the trial complete |
| 10 | ChiCTR2000031782 | A questionnaire investigation of hydroxychloroquine for its potential protective effect against novel COVID-19 | Observational study | 10/4/2020 | / | / | Not yet recruiting. | From 2020-04-10 To 2020-06-30 The time of sharing IPD Within 6 months after the trial complete |
| 11 | ChiCTR2000032487 | Study for using sulfate in the prevention and control of novel COVID-19 in high and low prevalence communities | Intervention study | 29/4/2020 | Hydroxychloroquine | Placebo | Not yet recruiting. | From 2020-03-01 To 2020-09-30 The time of sharing IPD Within 6 months after the trial complete |
bid, bis in die; IPD, information of participant data.